dehydroxymethylepoxyquinomicin and Nasopharyngeal-Neoplasms

Despite the demonstrated constitutive activation of NF-kappaB in nasopharyngeal carcinoma (NPC), the therapeutic potential of targeting this pathway has not been investigated. Here, we employed a small molecule inhibitor of NF-kappaB, DHMEQ (which mainly blocks nuclear translocation of activated NF-kappaB) and demonstrated significant inhibition of NPC cell proliferation, migration, invasion, as well as anchorage-independent growth. These antitumor effects were associated with induction of G(2)/M cell cycle arrest and apoptosis, and downregulation of NF-kappaB target genes (EGFR, cyclin D1 and survivin). This first demonstration of therapeutic benefits of NF-kappaB targeting in NPC implicates the importance of targeting this pathway in NPC.

Topics: Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclohexanones; G2 Phase; Humans; Intercellular Adhesion Molecule-1; Matrix Metalloproteinase 9; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; NF-kappa B; Vascular Endothelial Growth Factor A